Law360, New York (August 17, 2017, 8:54 PM EDT) -- A woman claiming that the blood thinner Xarelto caused gastrointestinal bleeding that required her hospitalization told a Louisiana federal judge on Thursday that Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. can’t put an end to her bellwether trial.
Responding to the drug companies’ motion for judgment of law, plaintiff Dora Mingo said they hadn’t shown that the jury doesn’t have a legally sufficient basis of evidence to decide in her favor. She said she showed evidence at trial that establishes that Xarelto is unreasonably dangerous because Janssen and Bayer didn’t adequately instruct physicians, including her own,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!